Sunesis Pharmaceuticals (Nasdaq: SNSS) 71.2% LOWER; announced regulatory updates from its interactions with the European Medicines Agency (EMA) and U.S ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE